Clinical trials: Malignant Tumor Liver
Pancreatic Cancer, Oesophageal Cancer
Nutrition in Gastrointestinal Tumors
Malnutrition and loss of muscle mass frequently occur in patients undergoing chemotherapy and can negatively effect therapy outcome.
- Conditions
- Pancreatic Cancer, Oesophageal Cancer, Colon Cancer, Liver Cancer
- Trial name
- NutriGIT (NCT04476082)
- Testing
- No intervention - observational study only
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- University Medicine Greifswald
Hepatocellular Carcinoma, Fibrolamellar Hepatocellular Carcinoma
Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards
The goal of this observational study is to compare the recommendations of the artificial intelligence clinical decision support system 'ADBoard', with the recommendations of physicians by tumor conferences in patients with…
- Conditions
- Hepatocellular Carcinoma, Fibrolamellar Hepatocellular Carcinoma, Cholangiocarcinoma, Perihilar, Intrahepatic Cholangiocarcinoma
- Trial name
- ADBoard (NCT05681949)
- Testing
- ADBoard
- Where
- Germany
- Volunteers
- 1,200 people
- Sponsor
- Charite University, Berlin, Germany
Liver Cancer, Ablation Techniques
The Safety and Efficacy of Irreversible Electroporation for the Treatment of Perivascular Liver Cancers
Malignant liver tumors are among the most common cancers worldwide, with over 10,000 new cases reported annually in Taiwan. Despite the availability of various treatment options, the prognosis for primary hepatocellular carcinoma…
- Conditions
- Liver Cancer, Ablation Techniques, Radiology
- Trial name
- NCT07214363
- Testing
- Irreversible Electroporation Ablation Generator
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Liver Metastases
Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment
This study will see whether collecting and analyzing needle biopsy samples from cancer liver metastases after a tumor ablation procedure will be able to identify cancer cells that are still alive.
- Trial name
- NCT04143516
- Testing
- [18-F]- FDG - PET, Tumor ablation (TA), PET/CT Scan
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
This pilot phase II trial studies how effective pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy are at treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or…
- Trial name
- NCT03457948
- Testing
- Arterial Embolization, Pembrolizumab, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Nicholas Fidelman, MD
Pancreatic Cancer Resectable
Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head
This randomized, controlled clinical trial compares the perioperative treatment with acetylsalicylic acid (aspirin) in patients with cancer of the pancreatic head.
- Trial name
- ASAP (NCT05637567)
- Testing
- Acetylsalicylic acid
- Volunteers
- 170 people
- Sponsor
- German Cancer Research Center
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Hepatocellular Carcinoma
Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection Recurrence
HBV DNA integration has been found in the chromosomes of about 90% of HBV-related HCC and the integration site is unique to individual HCC.
- Trial name
- NCT05823584
- Where
- Taiwan
- Volunteers
- 207 people
- Sponsor
- TCM Biotech International Corp.
Hepatocellular Carcinoma
Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents
This study aims to determine whether or not gadoxetate disodium (Eovist) enhanced magnetic resonance imaging (MRI) has a higher sensitivity for detecting hepatocellular carcinoma (Liver Cancer) comparison to multi-detector…
- Trial name
- NCT01341132
- Testing
- MRI Scan of the Liver enhanced with Eovist
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- San Francisco Veterans Affairs Medical Center
Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
This phase II trials studies how well pembrolizumab and vactosertib work after standard of care chemotherapy in patients with colorectal cancer that has spread to the liver that can be removed by surgery (resectable hepatic…
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8
- Trial name
- NCT03844750
- Testing
- Hepatectomy, Pembrolizumab, Vactosertib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Chloe Atreya, MD, PhD
Carcinoma, Hepatocellular
Cytotoxicity Induced by Tumor Lysate Pulsed Dendritic Cells Against Autologous Hepatocellular Carcinoma Cells
Hepatoma ranks the first on the cancer mortality list in Taiwan, and there are currently no other effective treatment options for advanced HCC.
- Trial name
- NCT00327496
- Testing
- DC vaccine
- Volunteers
- 10 people
- Sponsor
- Mackay Memorial Hospital
NSCLC, Prostate Cancer
Clinical Trial of TB511 in Advanced Solid Tumors
1. Study population [TB511 Monotherapy Cohort for Phase 1 and Phase 2a Clinical Trial] Patients with advanced solid tumors who are either refractory or intolerant to standard of care (SoC).
- Conditions
- NSCLC, Prostate Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06400160
- Testing
- TB511, Keytruda
- Volunteers
- 12 people
- Sponsor
- Twinpig Biolab, Inc.
Hepatic Carcinoma
ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation
To evaluate the ability of Erector spina Plane Block decrease postoperative pain and analgesia requirements in patients undergoing percutaneous Radiofrequency ablation of Hepatocellular Carcinomas.
- Trial name
- NCT05009550
- Testing
- Group ESP, Non-blocked Group
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- TC Erciyes University
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Solid Tumor
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
This was an open-label, Phase 1/2, dose escalation and signal finding study of derazantinib administered to patients with advanced solid tumors (Part 1; Dose Escalation/Food-effect Cohorts) or with advanced solid tumors with FGFR…
- Trial name
- NCT01752920
- Testing
- Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range
- Where
- 12 sites in United States, Italy
- Volunteers
- 119 people
- Sponsor
- Basilea Pharmaceutica
Liver Cancer, Liver Transplant; Complications
IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
This is a parallel assigned, open-label, perspective trial studying the safety and efficacy of intensity-modulated radiotherapy (IMRT) combined with PD-1 Blockade and Lenvatinib for Hepatocellular Carcinoma (HCC) with Vp3 Portal…
- Conditions
- Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma, Portal Vein Thrombosis
- Trial name
- iPLENTY-pvtt (NCT05339581)
- Testing
- intensity-modulated radiotherapy, Pembrolizumab, Sintilimab
- Where
- China
- Volunteers
- 78 people
- Sponsor
- RenJi Hospital
Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors
CapTemY90 for Grade 2/3 NET Liver Metastases
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety…
- Trial name
- CapTemY90 (NCT04339036)
- Testing
- Capecitabine Oral Product, Temozolomide Oral Product, transarterial radioembolization
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Percutaneous Tumor Ablation
Intra-procedural 360-degree Display for Performing Percutaneous Liver Tumor Ablation
Medical images used to guide treatment of tumor(s) are presently displayed on flat-panel monitors (like screens used with computers).
- Trial name
- NCT03500757
- Testing
- HoloLens
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Case Comprehensive Cancer Center
Adult Hepatocellular Carcinoma, Metastatic Malignant Neoplasm in the Liver
MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer
This pilot clinical trial studies magnetic resonance imaging (MRI)-guided stereotactic body radiation therapy (SBRT) in treating patients with liver metastases or liver cancer.
- Trial name
- NCT02683200
- Testing
- Image-Guided Adaptive Radiation Therapy, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Side-effect of Antibiotic
Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.
The aim of the study is to provide data on the pharmacokinetics (PK) of moxifloxacin (MXF) in serum and liver tissue of patients undergoing liver resection due to primary or secondary tumor of the liver.
- Trial name
- MOXI (NCT01302951)
- Testing
- Moxifloxacin 400 mg
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- University Hospital, Saarland